CSCI Logo

Cosciens Biopharma Inc (CSCI) Stock Forecast & Price Prediction

Live CSCI Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NASDAQ | Healthcare | Biotechnology

$2.87

+0.27 (10.38%)

12 Month Price Forecast For CSCI

$2.87
Current Price
$8.96M
Market Cap
0 Ratings
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to CSCI Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

CSCI Price Momentum

+3.6%
1 Week Change
-20.9%
1 Month Change
-45.3%
1 Year Change
+3.6%
Year-to-Date Change
-69.2%
From 52W High of $9.32
+20.6%
From 52W Low of $2.38

๐Ÿค” Considering Cosciens (CSCI)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 5, 2025 10:37 PM UTC

CSCI Analyst Ratings & Price Targets

Currently, there are no Wall Street analyst price targets or forecasts available for CSCI (Cosciens).

CSCI is currently trading at $2.87. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CSCI Analyst Consensus

0
Buy
0
Hold
0
Sell

CSCI Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $2.87

Latest CSCI Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CSCI.

Date Firm Analyst Rating Change Price Target
Nov 13, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $15.00
Aug 10, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $28.00
Jul 14, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $28.00
May 12, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $28.00
Apr 10, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $28.00
Mar 28, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $28.00
Mar 30, 2022 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $1.50
Oct 25, 2021 HC Wainwright & Co. Buy Initiates $0.00
Nov 9, 2015 Canaccord Genuity Buy Upgrade $0.00
Apr 14, 2015 H.C. Wainwright Buy Upgrade $0.00
Jul 17, 2014 H.C. Wainwright Buy Initiates $0.00
Jul 25, 2013 Euro Pacific Capital Hold Initiates $0.00
Jan 3, 2013 McNicoll Lewis Vlak Buy Upgrade $0.00
Dec 31, 2012 Canaccord Genuity Hold Maintains $2.50
Oct 12, 2012 Bloom Burton & Co. Sell Maintains $2.00

Stocks Similar to Cosciens Biopharma Inc

The following stocks are similar to Cosciens based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Cosciens Biopharma Inc (CSCI) Financial Data

Cosciens Biopharma Inc has a market capitalization of $8.96M with a P/E ratio of -1.5x. The company generates $4.83M in trailing twelve-month revenue with a 41.1% profit margin.

Revenue growth is +62,266.7% quarter-over-quarter, while maintaining an operating margin of -258.4% and return on equity of -100.3%.

Valuation Metrics

Market Cap $8.96M
Enterprise Value $-10,305,092
P/E Ratio -1.5x
PEG Ratio 0.0x
Price/Sales 1.9x

Growth & Margins

Revenue Growth (YoY) +62,266.7%
Gross Margin +51.1%
Operating Margin -258.4%
Net Margin +41.1%
EPS Growth +37.3%

Financial Health

Cash/Price Ratio +224.3%
Current Ratio 3.5x
Debt/Equity 8.1x
ROE -100.3%
ROA -37.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Cosciens Biopharma Inc logo

Cosciens Biopharma Inc (CSCI) Company Overview

About Cosciens Biopharma Inc

What They Do

Develops biopharmaceuticals and diagnostic tests.

Business Model

COSCIENS Biopharma Inc. focuses on developing and commercializing therapeutics and diagnostic tests, primarily through licensing agreements and partnerships with other firms and universities. The company generates revenue by selling its lead product, Macrilen, for growth hormone deficiency diagnosis, alongside other therapeutic products in various stages of development.

Additional Information

The company operates internationally, with a presence in Canada, the U.S., and several European countries. It has ongoing preclinical trials for treatments related to chronic hypoparathyroidism and amyotrophic lateral sclerosis, indicating a diverse pipeline in the biopharmaceutical space. COSCIENS Biopharma was previously known as Aeterna Zentaris Inc. and rebranded in August 2024.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.

Country

Canada

IPO Year

2000

Cosciens Biopharma Inc (CSCI) Latest News & Analysis

CSCI stock latest news image
Quick Summary

The company is focused on developing and commercializing natural-based products aimed at enhancing health and wellness.

Why It Matters

The focus on natural-based health products may indicate growth potential and market demand, potentially driving revenue and stock performance for the company.

Source: GlobeNewsWire
Market Sentiment: Neutral
CSCI stock latest news image
Quick Summary

COSCIENS Biopharma Inc. reported a cash balance of $20 million as of September 30, 2024, following merger integration with Ceapro Inc. and ongoing evaluations of its product pipeline.

Why It Matters

The successful merger integration and strong cash position suggest COSCIENS Biopharma is well-positioned for growth, potentially increasing investor confidence and stock value.

Source: GlobeNewsWire
Market Sentiment: Neutral
CSCI stock latest news image
Quick Summary

COSCIENS Biopharma Inc. announced the immediate resignation of Carolyn Egbert from its Board of Directors, as of October 8, 2024.

Why It Matters

Carolyn Egbert's resignation from COSCIENS' Board may signal potential instability or strategic shifts, impacting investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
CSCI stock latest news image
Quick Summary

COSCIENS Biopharma Inc. has appointed Pierre Labbรฉ to its board and as Chair of the Audit Committee, following Dennis Turpin's resignation, effective October 1, 2024.

Why It Matters

Leadership changes can impact company strategy and investor confidence. Pierre Labbรฉ's appointment may signal a shift in governance or focus, influencing stock performance and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
CSCI stock latest news image
Quick Summary

COSCIENS Biopharma Inc. (NASDAQ: CSCI, TSX: CSCI) announced updates on its merger integration with Ceapro Inc., including management team changes and business advancements.

Why It Matters

Merger updates and management changes can significantly impact COSCIENS' operational efficiency and market position, influencing investor sentiment and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
CSCI stock latest news image
Quick Summary

COSCIENS Biopharma's Phase 3 DETECT-trial for macimorelin in diagnosing Childhood Onset Growth Hormone Deficiency did not meet its primary efficacy endpoint, despite confirming safety in children.

Why It Matters

The failure to meet primary efficacy endpoints may lead to regulatory setbacks and impact COSCIENS Biopharma's stock performance, influencing investor confidence and potential market value.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About CSCI Stock

What is Cosciens Biopharma Inc's (CSCI) stock forecast for 2025?

Analyst forecasts for Cosciens Biopharma Inc (CSCI) are not currently available. The stock is trading at $2.87.

Is CSCI stock a good investment in 2025?

Analyst ratings for CSCI are not currently available. The stock is currently trading at $2.87. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CSCI stock?

Price predictions from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.

What is Cosciens Biopharma Inc's business model?

COSCIENS Biopharma Inc. focuses on developing and commercializing therapeutics and diagnostic tests, primarily through licensing agreements and partnerships with other firms and universities. The company generates revenue by selling its lead product, Macrilen, for growth hormone deficiency diagnosis, alongside other therapeutic products in various stages of development.

What is the highest forecasted price for CSCI Cosciens Biopharma Inc?

Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.

What is the lowest forecasted price for CSCI Cosciens Biopharma Inc?

Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.

What is the overall CSCI consensus from analysts for Cosciens Biopharma Inc?

Analyst ratings for CSCI are not currently available. The stock is trading at $2.87.

How accurate are CSCI stock price projections?

Stock price projections, including those for Cosciens Biopharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.